Glucocorticoids in autoimmune bullous diseases: are neutrophils the key cellular target?

Dagmar Simon; Luca Borradori; Hans-Uwe Simon

doi:10.1038/jid.2013.205

Glucocorticoids in autoimmune bullous diseases: are neutrophils the key cellular target?

J Invest Dermatol. 2013 Oct;133(10):2314-2315. doi: 10.1038/jid.2013.205.

Authors

Dagmar Simon¹, Luca Borradori², Hans-Uwe Simon³

Affiliations

¹ Department of Dermatology, University Hospital Bern, Inselspital, Bern, Switzerland. Electronic address: hus@pki.unibe.ch.
² Department of Dermatology, University Hospital Bern, Inselspital, Bern, Switzerland.
³ Institute of Pharmacology, University of Bern, Bern, Switzerland.

PMID: 24030648
DOI: 10.1038/jid.2013.205

Abstract

The newly observed nongenomic effects of glucocorticoids on signaling pathways operating in neutrophils in vitro will stimulate further investigations on pathogenic mechanisms and drug actions in bullous skin diseases.

Publication types

Comment

MeSH terms

Animals
Autoantibodies / immunology*
Epidermolysis Bullosa Acquisita / drug therapy*
Humans
Methylprednisolone / pharmacology*
Neutrophils / drug effects*
Pemphigoid, Bullous / drug therapy*

Substances

Autoantibodies
Methylprednisolone